GIP/GLP-1RA as adjunctive to automated insulin delivery in adults with Type 1 diabetes (the AID-JUNCT trial): Study protocol for a prospective, randomized, clinical trial
This is the first prospective study to investigate the safety and efficacy of tirzepatide (GIP/GLP1-RAs) as an adjuvant therapy to AID in T1D. This study may contribute unique data to significantly improving glucose and cardio-metabolic outcomes, re-directing attention to further treatment in T1D beyond insulin therapies.
Authors
- Thomas Züger (ORCID: https://orcid.org/0000-0001-6190-7405)
- Matthias Hepprich (ORCID: https://orcid.org/0000-0002-6905-6235)
- María Carolina Fragozo-Ramos (ORCID: https://orcid.org/0000-0002-6657-9989)
- G. Schenker
- Jaime Gallo‐Villegas (ORCID: https://orcid.org/0000-0002-6296-5110)
- José Garcia‐Tirado (ORCID: https://orcid.org/0000-0002-9970-2162)
Institutions
- University of Bern (CH)
- University of Basel (CH)
- University Hospital of Bern (CH)
- Universidad de Antioquia (CO)
- Municipality of Medellín (CO)
- Kantonsschule Olten (CH)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1371/journal.pone.0335060
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29